COVID-19 vaccines

Global Coronavirus (COVID-19) Vaccine Market to 2026 By Infection Type, Vaccine Type, Product Type, Route of Administration, Patient Type, End User, Region - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Health, Pharmaceutical, Coronaviridae, Medicine, Health sciences, Zoonoses, COVID-19 vaccines, Sarbecovirus, Bat virome, Clinical trials, COVID-19 vaccine, Severe acute respiratory syndrome, Coronavirus, COVID-19

The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period.
  • The Global Coronavirus Vaccine Market is driven by the increasing prevalence of this disease across different parts of the globe.
  • The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company, and region.

Statement from the Chief Public Health Officer of Canada on July 29, 2021

Retrieved on: 
Thursday, July 29, 2021
Articles, Health, COVID-19 vaccines, Clinical trials, RNA vaccines, Medical research, Health Canada, COVID-19 vaccine, Public Health Agency of Canada, Vaccination, National Advisory Committee on Immunization, Immunity passport

Through the Wellness Together Canada online portal, people of all ages across the country can access immediate, free and confidential mental health and substance use supports, 24 hours a day, seven days a week.

Key Points: 
  • Through the Wellness Together Canada online portal, people of all ages across the country can access immediate, free and confidential mental health and substance use supports, 24 hours a day, seven days a week.
  • The Public Health Agency of Canada(PHAC) provides regular updates on COVID-19 vaccines administered , vaccination coverage and ongoing monitoring of vaccine safety across the country.
  • Regardless of which SARS-CoV-2 variantsare predominating in an area, we know that vaccination, in combination with public health and individual measures, continue to work to reduce the spread of COVID-19.
  • As public health restrictions are eased, some increase in cases, particularly among unvaccinated populations, is not unexpected.

Swedish company ZandCell offers Russia 750 million dose vaccine capacity for Sputnik V and Aurora

Retrieved on: 
Thursday, July 29, 2021
COVID-19 pandemic in Russia, COVID-19 vaccines, Clinical trials, Medicine, Gamaleya Research Institute of Epidemiology and Microbiology, Science and technology in Russia, Vaccination, Sputnik V COVID-19 vaccine, Mass media, Sputnik, COVID-19 vaccine, COVID-19 vaccination in India

"We want either Sputnik V vaccine from Gamaleya or Aurora from Vector Institute.

Key Points: 
  • "We want either Sputnik V vaccine from Gamaleya or Aurora from Vector Institute.
  • I believe Sputnik V is the best vaccine in the world right now.
  • We are ready to manufacture 750 million doses per year and we offer our capacity to Russia.
  • For more information on ZandCell email: [email protected]
    Please visit the company's website at ZandCell.com or follow @ZandCell on Twitter.

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

Retrieved on: 
Tuesday, July 27, 2021
COVID-19 vaccines, COVID-19, Clinical trials, Medicine, Vaccination, Adenoviridae, Medical research, Vaccine controversies

Rubic was founded by a consortium of public health, medical, academia, vaccine technology, technology transfer and economic sector experts interested in addressing the regions specific challenges related to vaccine availability and affordability.

Key Points: 
  • Rubic was founded by a consortium of public health, medical, academia, vaccine technology, technology transfer and economic sector experts interested in addressing the regions specific challenges related to vaccine availability and affordability.
  • Establishing a vaccine manufacturing unit with the infrastructure, processing operations and capabilities for the manufacture and distribution of high-quality vaccines throughout the African continent.
  • Dyadic will facilitate technology transfer of the C1 Platform to Rubic through the completion of clinical trials.
  • The Rubic Consortium is made up of promoters of the project representing public health, medical, academia, vaccine technology, technology transfer and economics sectors.

CMMB, 81 Global Humanitarian and Faith-Based Organizations Call on Biden Administration to Provide Equitable Global Vaccine Distribution

Retrieved on: 
Monday, July 26, 2021
Medicine, Articles, Health, Medical research, COVID-19 vaccines, Clinical trials, Contemporary history, Politics, Presidency of Joe Biden, CMMB, COVID-19 vaccine, Joe Biden

In the letter , CMMB and the likeminded organizations urged the Biden Administration to:

Key Points: 
  • In the letter , CMMB and the likeminded organizations urged the Biden Administration to:
    3) Continue to distribute the vaccines that the U.S. has pledged to donate
    5) Encourage other developed nations to take similar actions.
  • CMMB and our fellow humanitarian organizations are calling on the Biden Administration to commit to greater vaccine production and distribution to achieve equity and prevent more deadly outbreaks.
  • In calling on the Biden Administration to distribute surplus vaccines, Ms.
  • State governments and hospital systems in the U.S. are sitting on millions of surplus COVID-19 vaccine doses as expiration dates approach.

BioNTech Provides Update on Plans to Develop Sustainable Solutions to Address Infectious Diseases on the African Continent

Retrieved on: 
Monday, July 26, 2021
BioNTech, Health sciences, Medicine, Medical research, COVID-19, COVID-19 vaccines, Clinical trials, RNA vaccines, Pfizer–BioNTech COVID-19 vaccine, Vaccine, Africa Centres for Disease Control and Prevention, Deployment of COVID-19 vaccines

The second objective is the development of sustainable vaccine production and supply solutions on the African continent.

Key Points: 
  • The second objective is the development of sustainable vaccine production and supply solutions on the African continent.
  • BioNTech is exploring possibilities to set up state-of-the-art mRNA manufacturing facilities, either with partners or on its own.
  • The facilities are expected to manufacture various mRNA-based vaccines upon approval to ensure sustainable supply operations.
  • BioNTech plans to co-locate its African manufacturing capabilities with the technology transfer hubs under development by the WHO, in alignment with the African manufacturing strategy created by the Africa CDC.

Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria vaccine, and the set-up of Manufacturing Infrastructures in Africa

Retrieved on: 
Monday, July 26, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Medical Supplies, Medicine, Medical specialties, COVID-19, COVID-19 vaccines, Clinical trials, Medical research, BioNTech, RNA vaccines, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine, Vaccine, RNA vaccine

The companys project is part of a programme by the kENUP Foundation to accelerating the eradication of Malaria.

Key Points: 
  • The companys project is part of a programme by the kENUP Foundation to accelerating the eradication of Malaria.
  • BioNTech aims to develop a safe and highly effective mRNA vaccine with durable protective immunity for prevention of malaria and disease associated mortality.
  • BioNTech and Pfizer pledged to deliver two billion doses of their COVID-19 vaccine to middle- and low-income countries over the next 18 months.
  • BioNTechs work on Malaria and end-to-end vaccine manufacturing in Africa will initially be fully funded by the company from internal resources.

Palantir and U.S. Government to Continue Work on COVID-19 Vaccine Distribution

Retrieved on: 
Monday, July 26, 2021
White House, Federal Government, Public policy, Government, Health, Security, Technology, Software, General Health, Medicine, COVID-19 vaccines, Clinical trials, Medical research, Medical specialties, Health sciences, BioNTech, COVID-19 vaccine, Vaccine, Palantir, Palantir Technologies

Palantir will work with HHSs Office of the Chief Information Officer (OCIO) and provide its software platform to help manage the U.S. COVID-19 vaccine distribution strategy, enable international distribution, and improve the equity and efficacy of vaccine programs.

Key Points: 
  • Palantir will work with HHSs Office of the Chief Information Officer (OCIO) and provide its software platform to help manage the U.S. COVID-19 vaccine distribution strategy, enable international distribution, and improve the equity and efficacy of vaccine programs.
  • Palantirs software enables organizations to improve their data-driven decision-making process by integrating disparate data sources into a single common operating picture.
  • Palantir was commissioned in mid-2020 by the Department of Health and Human Services to build Tiberius, a software platform it uses to track vaccine production, distribution, and administration across the United States.
  • For this renewed contract, Palantir will continue to support Tiberius, which gives local, state and federal health officials a comprehensive platform to track vaccine distribution and administration.

Health Care Communications Experts Raise Over $1.6 Million For Video Campaign To Reverse Vaccine Hesitancy

Retrieved on: 
Monday, July 26, 2021
Medicine, Medical research, Health sciences, COVID-19 vaccine, Medical specialties, Vaccine, COVID-19 vaccines, Clinical trials

Video ads will run 130 million times in under-vaccinated parts of the country.

Key Points: 
  • Video ads will run 130 million times in under-vaccinated parts of the country.
  • The network of communications professionals have come together to create a nonprofit organization, Face2Face America (F2FA), focused on ensuring as many eligible Americans get the Covid-19 vaccine as possible.
  • They reached out to a range of health care partners to secure the funding for the digital media campaign.
  • Recent research has shown that video-based messaging from health care professionals and community members is a highly effective manner of influencing vaccine hesitant Americans.

INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Monday, July 26, 2021
Medical research, Inovio Pharmaceuticals, Health sciences, Medicine, Medical specialties, Vaccine, Clinical trials, COVID-19 vaccines, Inovio COVID-19 vaccine

PLYMOUTH MEETING, Pa., July 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2021 financial results will be released after the market close on August 9, 2021.

Key Points: 
  • PLYMOUTH MEETING, Pa., July 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2021 financial results will be released after the market close on August 9, 2021.
  • Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m.
  • ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19.
  • A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx .